Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-12-27 5:23 pm Sale | 2024-12-23 | 13D | Stoke Therapeutics, Inc. STOK | Skorpios Trust | 6,906,181 13.000% | -2,000,000 (-22.46%) | Filing History |
| 2024-11-14 9:00 pm Purchase | 2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK | Redmile Group LLC | 4,713,509 9.000% | 2,088,003 (+79.53%) | Filing History |
| 2024-11-14 4:24 pm Purchase | 2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK | BAKER BROS. ADVISORS LP | 4,368,443 8.300% | 4,368,443 (New Position) | Filing History |
| 2024-11-14 09:00 am Purchase | 2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK | Lynx1 Capital Management LP | 5,187,191 9.900% | 2,230,273 (+75.43%) | Filing History |
| 2024-11-12 5:56 pm Unchanged | 2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK | The Vanguard Group | 2,759,247 5.240% | 0 (Unchanged) | Filing History |
| 2024-11-04 1:56 pm Purchase | 2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK | The Vanguard Group | 2,759,247 5.240% | 1,157,202 (+72.23%) | Filing History |
| 2024-09-23 4:22 pm Sale | 2024-09-19 | 13D | Stoke Therapeutics, Inc. STOK | Skorpios Trust | 8,906,181 16.900% | -1,937,500 (-17.87%) | Filing History |
| 2024-07-08 4:32 pm Purchase | 2024-06-30 | 13G | Stoke Therapeutics, Inc. STOK | BlackRock Inc. BLK | 5,409,169 10.400% | 5,409,169 (New Position) | Filing History |
| 2024-04-18 4:18 pm Sale | 2024-04-17 | 13D | Stoke Therapeutics, Inc. STOK | Skorpios Trust | 10,843,681 23.400% | -3,600,000 (-24.92%) | Filing History |
| 2024-02-26 10:38 am Purchase | 2023-12-29 | 13G | Stoke Therapeutics, Inc. STOK | Cowen Financial Products LLC | 3,721,659 8.300% | 1,445,553 (+63.51%) | Filing History |
| 2024-02-26 10:36 am Purchase | 2023-01-04 | 13G | Stoke Therapeutics, Inc. STOK | Cowen Financial Products LLC | 2,276,106 5.770% | 1,028,029 (+82.37%) | Filing History |
| 2024-02-14 4:26 pm Sale | 2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK | Redmile Group LLC | 2,625,506 5.900% | -1,541,469 (-36.99%) | Filing History |
| 2024-02-14 09:20 am Purchase | 2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK | Lynx1 Capital Management LP | 2,956,918 6.600% | 292,760 (+10.99%) | Filing History |
| 2024-02-14 07:44 am Purchase | 2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK | RTW Investments, LP | 4,131,045 9.300% | 260,064 (+6.72%) | Filing History |
| 2024-02-09 2:51 pm Purchase | 2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK | MORGAN STANLEY MS | 3,358,375 7.500% | 910,161 (+37.18%) | Filing History |
| 2024-02-09 09:49 am Sale | 2024-02-08 | 13G | Stoke Therapeutics, Inc. STOK | FMR LLC | 5,000 0.011% | -3,029,649 (-99.84%) | Filing History |
| 2023-11-06 4:55 pm Purchase | 2023-10-26 | 13G | Stoke Therapeutics, Inc. STOK | Lynx1 Capital Management LP | 2,664,158 6.000% | 2,664,158 (New Position) | Filing History |
| 2023-02-14 10:08 am Purchase | 2022-12-31 | 13G | Stoke Therapeutics, Inc. STOK | RTW Investments, LP | 3,870,981 9.800% | 226,733 (+6.22%) | Filing History |
| 2023-02-10 11:50 am Purchase | 2022-12-30 | 13G | Stoke Therapeutics, Inc. STOK | MORGAN STANLEY MS | 2,448,214 6.200% | 2,448,214 (New Position) | Filing History |
| 2023-02-09 12:31 pm Purchase | 2023-02-09 | 13G | Stoke Therapeutics, Inc. STOK | FMR LLC | 3,034,649 7.696% | 479,850 (+18.78%) | Filing History |